The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial launch generated substantial returns, the lapse of its exclusive rights opened the avenue to cheaper versions, dramatically diminishing sales. This poses a unique challenge for firms depending on comparable blockbuster offerings, suggesting t

The history of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in income, its patent expiration created a flood of knock-off medications, significantly eroding its market share . While specific businesses may attempt to capitalize on related treatments , the ex